Phathom Pharmaceuticals (PHAT) Interest Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Interest Expenses data on file, last reported at $15.8 million in Q1 2026.

• Interest Expenses for Q1 2026 came in at $15.8 million, down 12.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.8 million (down 9.7% YoY), and the FY2025 annual result was $68.1 million, down 5.41% from the prior year.
• Interest Expenses fell to $15.8 million in Q1 2026 per PHAT's latest filing, from $16.4 million in the prior quarter.
• Over five years, Interest Expenses peaked at $18.6 million in Q4 2024 and troughed at $2.8 million in Q1 2022.
• A 5-year average of $13.2 million and a median of $15.8 million in 2026 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2025: Interest Expenses jumped 524.71% in 2022, then slipped 12.85% in 2025.
• A 5-year view of Interest Expenses shows it stood at $9.6 million in 2022, then jumped by 35.69% to $13.0 million in 2023, then surged by 42.7% to $18.6 million in 2024, then decreased by 11.69% to $16.4 million in 2025, then slipped by 3.79% to $15.8 million in 2026.
• Business Quant data shows PHAT's Interest Expenses at $15.8 million in Q1 2026, $16.4 million in Q4 2025, and $16.1 million in Q3 2025.